Hypertrophic pulmonary osteoarthropathy (HPO) associated with non-small cell lung cancer in a 58-year-old man was accompanied by an elevated serum level of growth hormone (GH). HPOrapidly disappeared after resection of the primary tumor and the elevation of serum GHwas resolved. Immunohistochemically the tumor contained growth hormone-releasing hormone (GHRH)but not GH.
Introduction
Hypertrophic pulmonary osteoarthropathy (HPO) is a clinical syndrome presenting with osteitis of the long bones, arthritis, and clubbing of the fingers and toes. It is usually associated with lung cancer or other chronic pulmonary or pleural diseases. It has been found in about 3-10% of patients who have lung cancer (1, 2) . The exact epiology of HPOin patients with lung cancer remains uncertain, however, vagal nerve stimulation or endocrine substances produced by tumors, such as estrogen, ACTH,GHand other vasodilative substances may be factors. To our knowledge, this is the second reported case of non-small cell lung cancer which was immunohistochemically positive for GHRHand showed high serum level of GHassociated with HPO.
Case Report
A 58-year-old man was admitted to our hospital in March 1999 with chief complaints of two months of cough productive for hemoptysis and right pleuritic pain. Ten months before admission, he sufferd severe arthralgia of both extremities and ankles. He was maintained on indomethacin therapy for relief of pain. Five months before admission, he developed clubbing of the fingers and toes. Medical history was unremarkable. He had smoked about one pack of cigarettes a day for the past 40 years. Physical examination on admission confirmed the bilateral swelling of legs and clubbing of the fingers ( Fig. 1 ) and toes with a marked pretibial pain on palpation, but there was no acromegaly in his facial features. Lymphadenopathy and gynecomastia were not found. Initial investigation revealed an elevated serum level of alkaline phosphatase at 342 IU// (normal range, 75-230 IU//), C-reactive protein of 2.79 mg/dl (normal range, <0.40 mg/dl) and carcinoembryonic antigen of 5.6 ng/ml (normal range, 0.0-5.0 ng/ml). The fasting blood glucose level was 90 mg/dl and hemoglobin Ale level was 6.0% (normal range, 4.3-5.8%). The fasting serum GHlevel 0.74 ng/ml (normal range, 0.03-0.42 ng/ml) and all other serum hormone levels, including ACTH, antidiuretic hormone, parathyroid hormone, prolactin and humanchorionic gonadotropin were within normal range. Anti-nuclear antiboby, rheumatoid arthritis particle agglutination and transforming growth factor-pl were negative. Chest roentgenography and chest computed tomographic scan showed a mass lesion (6 cm in diameter) in the right upper lobe ( Fig. 2A, B) . Mediastinal, hilar lymphadenopathy and distant metastasis were not found. Bronchoscopicfindings revealed complete obstruction at the orifice of the right B2caused by tumor. A biopsy specimen confirmed the diagnosis of adenocarcinoma. The clinical TMNclassification was T2 NOM0, stage IB. Bone scintigraphy showed a pericortical concentration along the femoral and tibial shafts and ankles ( Fig. 3 left) . Roentgenography of the tibia and fibula demonstrated subperiosteal proliferation. MRI of the pituitary gland did not show pituitary adenoma or hyperplasia. Right upper lobectomy combined with mediastinal and hilar lymph node dissection was performed. Swelling and arthralgia of the lower extremities disappeared within a few days after operation, and the serum level of GHand hemoglobin Ale fell to the normal range. Bone scintigraphy showed nearly completeresolution of the activity two monthsafter operation (Fig. 3 right) . However, X-ray examination showed that periosteal changes and clubbing of the fingers remained. Six months later, the patient had no evidence of relapse. At pathologic examination of the resected specimen, the tumor was well-demarcated and composed of well differentiated adenocarcinoma componentsshowing papillary growth and undifferentiated components comprising round to oval shaped neoplastic cells with prominent nucleoli (Fig. 4A) . Massive tumor necrosis and hemorrhage were intermingled in the lesion but no pleural invasion was seen. Neither osteoid, cartilage nor rhabdoid cells was found in the tumor. By immunohistochemical staining using the avidin-biotin complex method and diaminobenzidine as a chromogen, anti-alpha-sarcomeric actin (DAKO, Carpinteria, CA, USA), myoglobin (Nichirei, Tokyo), alpha-smooth muscle actin (DAKO) antibodies were negative in the tumor. So we diagnosed the lesion as not true carcinosarcoma but well differentiated adenocarcinoma with undifferentiated components. Immunohistochemical staining with anti-GH antibody (DAKO)was entirely negative in the tumor but that with anti-GHRH (Biogenesis Inc., Kingston, NH, USA) was positive in the undifferentiated components (Fig. 4B) .
Discussion
About 80% of pulmonary lesions associated with HPOare lung cancers, pleural tumors makeup 10%,and a miscellaneus group of intrathoracic malignancies account for 5% (2) . Chronic suppurative pulmonary inflammatory disease and congenital cyanotic heart disease are non-malignant causes of HPOcontributing to the remainder. HPOis usually detected before or at the time of diagnosis of the underlying disease, but occasionally is manifested years later. In this case, symptoms predated the diagnosis of primary lung cancer by ten months. The appearance of radionuclide bone images are correlated with clinical signs and symptoms. Radionuclide studies are more sensitive than radiography in the detection of HPO (3) (4) (5) . In the present case, the postoperative activity of bone scintigraphy in the area of HPOdiminished markedly. However, radiographs still showed periosteal changes. This indicates that dynamic changes occurring in the bones are monitored more precisely by bone scintigraphy than by anatomical changes seen on the radiographs. The pathogenesis of HPOis not fully understood. Opinions are divided between neurogenic and humoral mechanisms, though both could be simultaneously active (6). Responsible hormones are not entirely evident. Growth hormone produced by pulmonary tumors has also been implicated occasionally (7-10). Steiner and associates reported a patient whohad typical osteoarthropathy, adenocarcinoma and high plasma GHlevels (7). They found that the high level of GHreturned to normal after resection of the tumor and that the patient had relief of clinical symptoms. Dupont et al reported that malignant tumor cells might be able to synthesize and secrete GHor GHlike substances (8). It is confirmed that lung tumor cells are capable of synthesizing immunoreactive GH. On the other hand, Beck and Burger claimed that plasma GHlevels were labile and might become elevated in many different conditions and added that it was difficult to ascribe the pathogenic role to GH in HPO(9). Ectopic production of GHhas been suggested as the cause of HPOassociated with lung cancer, but there has only been one previous report of non-small cell lung cancer which was immunohistochemically positive for GHRHassociated with HPO (10). The present case had an elevated serum level of GHwhich was confirmed by immunohistochemical analysis of GHRHin the primary lesion. The high level of GHreturned to normal after resection of the tumor, and the pain and swelling rapidly disappered within a few days after operation. These findings suggest that the ectopically produced GHRH in the tumor stimulated secretion of GH from the pituitary body and that GHwas Figure 3 . Bone scintigraphy showed a pericortical concentration along the femoral and tibial shafts and ankle preoperatively (left) . Bone scintigraphy showednearly complete resolution ol the activity two months after operation (right). a contributing factor in HPO.Wedid not recognize symptoms associated with the presence of high GHlevel except for HPO and mild abnormal glucose tolerance in the present patient.
Several investigators report that not all patients with HPOhave high GHlevels, and the presence of high GHlevels does not always lead to clinically detectable effects, such as HPO(9). It is therefore concluded that GHand GHRHcan be some of the factors responsible for HPOin non-small cell lung cancer.
